Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Enveric Biosciences Inc (ENVB)

Enveric Biosciences Inc (ENVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,795
  • Shares Outstanding, K 21,432
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,860 K
  • 60-Month Beta 1.77
  • Price/Sales -3.18
  • Price/Cash Flow N/A
  • Price/Book 2.99
Trade ENVB with:

Options Overview

Details
  • Implied Volatility 0.00%
  • Historical Volatility 147.00%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.92
  • Growth Rate Est. (year over year) +52,131.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.54 +76.62%
on 08/17/21
3.74 -27.27%
on 09/10/21
+1.11 (+68.94%)
since 08/16/21
3-Month
1.54 +76.62%
on 08/17/21
3.74 -27.27%
on 09/10/21
+0.48 (+21.43%)
since 06/16/21
52-Week
1.54 +76.62%
on 08/17/21
15.04 -81.91%
on 12/28/20
-2.20 (-44.72%)
since 09/16/20

Most Recent Stories

More News
Enveric Biosciences Announces MagicMed Industries' Presentations at the Following Investor Conferences in September

/PRNewswire/ --  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced...

ENVB : 2.72 (+2.64%)
Should Enveric Biosciences be in Your Stock Portfolio?

Enveric Biosciences (ENVB) garnered significant market attention, announcing its proposed acquisition of MagicMed in May 2021. However, is it smart to bet on the stock now, as it has yet to generate revenue?...

ENVB : 2.72 (+2.64%)
Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders

/PRNewswire/ -- (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel therapeutic drugs to improve the quality of life for cancer patients, Chief Executive...

ENVB : 2.72 (+2.64%)
New CBD Trials Point the Way for Enveric, MagicMed

Whitefish, Montana--(Newsfile Corp. - August 2, 2021) - (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries,...

ENVB : 2.72 (+2.64%)
CNFN : 0.0848 (-0.35%)
Enveric Bio's Acquisition of MagicMed Accentuates Strengths of Each Company

Whitefish, Montana--(Newsfile Corp. - July 12, 2021) -   (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries,...

ENVB : 2.72 (+2.64%)
CNFN : 0.0848 (-0.35%)
Enveric Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma

/PRNewswire/ --  (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that...

ENVB : 2.72 (+2.64%)
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates ARPO, ALTA, ENVB, FBNC, MCF; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

ARPO : 2.20 (-0.90%)
ALTA : 40.03 (-1.33%)
ENVB : 2.72 (+2.64%)
FBNC : 39.49 (-0.30%)
MCF : 3.87 (-1.78%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Enveric Biosciences, Inc. - ENVB

/PRNewswire/ --

ENVB : 2.72 (+2.64%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CNST, FMBI, SWN, ENVB, MLND; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CNST : 33.99 (+0.06%)
FMBI : 17.87 (-0.17%)
SWN : 5.10 (-5.20%)
ENVB : 2.72 (+2.64%)
MLND : 15.9000 (-5.36%)
Lifshitz Law Firm, P.C. Announces Investigation of CLDR, DTRCD, DCRN, ENVB, PACX, SNX, XERS, and SBBP

/PRNewswire/ --

CLDR : 15.95 (+0.13%)
DTRCD : 5.6500 (-2.85%)
DCRN : 9.89 (unch)
ENVB : 2.72 (+2.64%)
PACX : 9.94 (-0.10%)
SNX : 119.06 (+0.33%)
XERS : 2.53 (-0.78%)
SBBP : 2.09 (-0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Enveric Biosciences Inc. is a patient-centric biotechnology company endeavoring to enhance the lives of Cancer Treatments with novel cannabinoid medicines. Enveric Biosciences Inc., formerly known as AMERI Holdings Inc., is based in NAPLES, Fla.

See More

Key Turning Points

3rd Resistance Point 3.09
2nd Resistance Point 2.97
1st Resistance Point 2.84
Last Price 2.72
1st Support Level 2.59
2nd Support Level 2.47
3rd Support Level 2.34

See More

52-Week High 15.04
Fibonacci 61.8% 9.88
Fibonacci 50% 8.29
Fibonacci 38.2% 6.70
Last Price 2.72
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar